4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Thykamine (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors PurGenesis Technologies
- 09 Nov 2017 Status changed from planning to recruiting according to a Devonian media release.
- 03 Jul 2017 New trial record
- 22 Jun 2017 According to a Devonian Health Group media release, this study is planned to start in end of june 2017.